Trial Profile

Effects of CYP2B6 genetic polymorphisms on efavirenz pharmacokinetics, autoinduction and drug interactions in healthy volunteers

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Caffeine; Efavirenz; Midazolam; Omeprazole; Tolbutamide
Indications Anxiety disorders; Duodenal ulcer; Dyspepsia; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Helicobacter infections; HIV-1 infections; Peptic ulcer; Type 2 diabetes mellitus; Zollinger-Ellison syndrome
Focus Pharmacogenomic; Pharmacokinetics; Therapeutic Use

Most Recent Events

26 Sep 2014 Biomarkers information updated
11 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
11 Oct 2011 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com